2. Search Result
Search Result
Results for "

synergistic effect

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

7

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155036
    Z1078601926

    		Dopamine Transporter Neurological Disease
    Z1078601926 is an allosterical inhibitor of human dopamine transporter (hDAT). Z1078601926 has synergistic effect with Nomifensine (HY-B1110) .
    Z1078601926
  • HY-W035709
    Hydrocinchonine

    Dihydrocinchonine

    		 Apoptosis Cancer
    Hydrocinchonine (Dihydrocinchonine) is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel in MES-SA/DX5 cells .
    Hydrocinchonine
  • HY-152848
    Fulzerasib

    IBI351; GFH925

    		 Ras Cancer
    Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .
    Fulzerasib
  • HY-164460
    AZD1897

    		Pim Cancer
    AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .
    AZD1897
  • HY-108932
    Gemcitabine monophosphate

    Gemcitabine 5′-phosphate

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate
  • HY-153788
    CK2-IN-7

    		Casein Kinase Cancer
    CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer .
    CK2-IN-7
  • HY-156573
    DGKα&ζ-IN-1

    		DGK Cancer
    DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .
    DGKα&ζ-IN-1
  • HY-122430
    Rosaramicin

    		Others Others
    Rosaramicin is a macrolide antibiotic that binds to the ribosomal P site and produces a synergistic effect with puromycin. This synergistic effect may be related to the interaction between the A and P sites. At the same time, its binding activity is affected by multiple substances.
    Rosaramicin
  • HY-108932A
    Gemcitabine monophosphate disodium

    Gemcitabine 5′-phosphate disodium

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate disodium
  • HY-144019
    18:0 EPC chloride

    		Liposome Infection
    18:0 EPC chloride is a synthetic cationic phospholipid. 18:0 EPC chloride (at the critical synergistic concentrations of 2.34-2.93 μM) significantly improves the inactivation effect of eugenol against Escherichia coli .
    18:0 EPC chloride
  • HY-160409
    TopBP1-IN-1

    		Others Cancer
    TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .
    TopBP1-IN-1
  • HY-117443
    IWP-051

    		Guanylate Cyclase Cardiovascular Disease
    IWP-051 is an agonist for soluble guanylate cyclase with an EC50 of 290 nM. IWP-051 stimulates the generation of cGMP, and exhibits the synergistic effect with NO. IWP-051 exhibits good pharmacokinetic characteristics in rats .
    IWP-051
  • HY-106892
    BW 348U87

    348U87

    		 DNA/RNA Synthesis Infection
    BW 348U87 is an inhibitor for ribonucleotide reductase, which exhibits synergistic effect with Acyclovir (HY-17422), potentiate the antiviral activity of Acyclovir against herpes simplex virus (HSV) in athymic nude mouse model .
    BW 348U87
  • HY-19666
    DPI 201-106
    1 Publications Verification

    SDZ 201106

    		 Sodium Channel Cardiovascular Disease
    DPI 201-106 (SDZ 201106) is a cardiotonic agent with a synergistic sarcolemmal and intracellular mechanism of action. DPI 201-106 shows cardioselective modulation of voltage-gated sodium channels (VGSCs) resulting in a positive inotropic effect .
    DPI 201-106
  • HY-161870
    Antibiotic adjuvant 1

    		Antibiotic Infection
    Antibiotic adjuvant 1 (compound 3e) is an antibiotic adjuvant that presents insufficient antibacterial activity (MIC > 128 µg/mL) and potentiate the activity of Cloxacillin (HY-B0466A)(66-fold) with synergistic effect .
    Antibiotic adjuvant 1
  • HY-B1843
    Fuberidazole

    BAY 33172; Furidazole

    		 Fungal Infection
    Fuberidazole (BAY 33172; Furidazole) is a fungicide. Fuberidazole shows a synergistic effect with cucurbituril (CB) macromolecules, such as CB7 and CB8. Studies have shown that, CB8 induces pKa shifts on Fuberidazole. Fuberidazole significantly inhibits the growth of B. cinerea .
    Fuberidazole
  • HY-P3607
    GHRF, bovine

    bGRF(1-44)-NH2

    		 GHSR Endocrinology
    GHRF, bovine (bGRF(1-44)-NH2) is the bovine growth hormone (GH)-releasing factor (GHRF). GHRF, bovine increases the release of bovine GH, and shows a synergistic effect with Hydrocortisone (HY-N0583) .
    GHRF, bovine
  • HY-P99536
    Tagraxofusp

    SL-401

    		 Interleukin Related Cancer
    Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
    Tagraxofusp
  • HY-N10313
    Dehydrobruceine B

    		Bcl-2 Family Keap1-Nrf2 Apoptosis Cancer
    Dehydrobruceine B, a quassinoid, can be isolated from Brucea javanica. Dehydrobruceine B shows a synergistic effect with Cisplatin (HY-17394) to induce apoptosis via mitochondrial method. Dehydrobruceine B increases apoptosis-inducing factor (AIF) and Bax expression and suppresses Keap1-Nrf2 .
    Dehydrobruceine B
  • HY-161152
    DNA relaxation-IN-1

    		DNA/RNA Synthesis Cancer
    DNA relaxation-IN-1 (compound 27) is a DNA Ligase 1 (DNA Lig1) inhibitor, which inhibits DNA ligation and disrupts Lig I’s DNA relaxation activity. DNA relaxation-IN-1 combined with Topotecan (HY-13768) exhibits a synergistic antiproliferative effect on colorectal cancer cells .
    DNA relaxation-IN-1
  • HY-161383
    CHK1-IN-9

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .
    CHK1-IN-9
  • HY-B1843R
    Fuberidazole (Standard)

    		Fungal Infection
    Fuberidazole (Standard) is the analytical standard of Fuberidazole. This product is intended for research and analytical applications. Fuberidazole (BAY 33172; Furidazole) is a fungicide. Fuberidazole shows a synergistic effect with cucurbituril (CB) macromolecules, such as CB7 and CB8. Studies have shown that, CB8 induces pKa shifts on Fuberidazole. Fuberidazole significantly inhibits the growth of B. cinerea .
    Fuberidazole (Standard)
  • HY-118013
    NDM-1 inhibitor-2

    		Others Infection
    NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced .
    NDM-1 inhibitor-2
  • HY-161516
    HDAC6-IN-42

    		HDAC Cancer
    HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC50=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research .
    HDAC6-IN-42
  • HY-N1791
    3,5-Diprenyl-4-hydroxybenzaldehyde

    		Others Infection
    3, 5-diprenyl-4-hydroxybenzaldehyde is an isoprene phenyl butyl aldehyde. 3, 5-diprenyl-4-hydroxybenzaldehyde had the ability to inhibit biofilm formation in strains. 3, 5-diprenyl-4-hydroxybenzaldehyde can be used to study the potential synergistic effect of clinically relevant antibiotics .
    3,5-Diprenyl-4-hydroxybenzaldehyde
  • HY-106072
    Vinzolidine

    LY 104208

    		 Microtubule/Tubulin Cancer
    Vinzolidine is a semisynthetic derivative of the catharanthus alkaloid. Vinzolidine exerts its cytotoxic effect on tumor cells by interfering with microtubulin polymerization, thereby inhibiting cell division. Vinzolidine can be utilized in research to investigate synergistic effects when combined with other chemotherapeutic agents or biologic therapies, as well as to study cancer cells' tolerance or resistance to these treatments, and to explore approaches to overcome such obstacles .
    Vinzolidine
  • HY-167715
    Traxanox

    		Others Inflammation/Immunology
    Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
    Traxanox
  • HY-159890
    MTI013

    		SARS-CoV Infection
    MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .
    MTI013
  • HY-148493
    MK-3402

    		Bacterial Infection
    MK-3402 (Compound303) is a metallo-beta-lactamase inhibitor, with IC50 values of 0.53, 0.25 and 0.169 nM against IMP-1, NDM-1, and VIM-1, respectively. MK-3402 can be used in bacterial research and shows a synergistic effect when used in combination with beta-lactam antibiotics .
    MK-3402
  • HY-161765
    iHSP110-33

    		HSP STAT Cancer
    iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
    iHSP110-33
  • HY-149155
    o-Cymen-5-ol

    		Others Infection
    o-Cymen-5-ol is a broad-spectrum antimicrobial agent with direct antimicrobial activity. o-Cymen-5-ol showed effective minimum inhibitory concentrations (MICs) against a variety of bacteria and fungi, such as Streptococcus mutans and Candida albicans. The combination of o-Cymen-5-ol and zinc showed synergistic effects, enhancing the inhibitory effect against oral pathogens. o-Cymen-5-ol was able to inhibit the glycolysis process and co-enhanced this effect with zinc. o-Cymen-5-ol showed a stronger antibacterial effect in toothpaste than placebo .
    o-Cymen-5-ol
  • HY-159585
    CYP51-IN-20

    		Cytochrome P450 Fungal Infection
    CYP51-IN-20 (compound 5b) is an inhibitor of CYP51 and has antifungal activity. CYP51-IN-20 has a significant inhibitory effect on Candida albicans ATCC 10231, downregulates ERG11 (Cyp51) gene expression, and significantly reduces the yeast-to-hyphae morphological transition. CYP51-IN-20 can synergize with Voriconazole (HY-76200) to occupy the entire CYP51 binding site and exert a synergistic inhibitory effect in the Glechoma moth model .
    CYP51-IN-20
  • HY-149881
    Quorum sensing-IN-2

    		Bacterial Infection
    Quorum sensing-IN-2 (compound 23e) is a quorum sensing inhibitor, which can reduce the pathogenicity of bacteria without affecting bacterial growth. Quorum sensing-IN-2 inhibits bacterial infections with little hemolytic activity. Quorum sensing-IN-2 shows synergistic effect with Ciprofloxacin (HY-B0356) in the bacteremia model infected with P. aeruginosa PAO1 .
    Quorum sensing-IN-2
  • HY-128355A
    (R)-IDO/TDO-IN-1

    		Indoleamine 2,3-Dioxygenase (IDO) Others Cancer
    (R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .
    (R)-IDO/TDO-IN-1
  • HY-109134A
    Pizuglanstat hydrate

    TAS-205

    		 Prostaglandin Receptor Inflammation/Immunology
    Pizuglanstat hydrate (TAS-205) is a hematopoietic prostaglandin D synthase (HPGDS) inhibitor. TAS-205 selectively inhibits the synthesis of prostaglandin D2 (PGD2) in cell-based enzymatic tests and in vivo models, and effectively reduces the entry of eosinophils into the nasal cavity and late-stage nasal congestion. When used in combination with montelukast (HY-13315A), TAS-205 showed a significant synergistic inhibitory effect; when used in combination with fexofenadine (HY-B0801A), it also had a certain inhibitory effect on early and late nasal congestion.
    Pizuglanstat hydrate
  • HY-155248
    HL23

    		HDAC Cancer
    HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .
    HL23
  • HY-144036
    DNA-PK-IN-3

    		DNA-PK Cancer
    DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4) .
    DNA-PK-IN-3
  • HY-149894
    MC-1-F2

    		Biochemical Assay Reagents Cancer
    MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .
    MC-1-F2
  • HY-B0317F
    Amlodipine hydrochloride

    		Calcium Channel Infection
    Amlodipine hydrochloride is a biologically active drug used to lower blood pressure and prevent chest pain. Amlodipine hydrochloride has shown synergistic effects with antimicrobial drugs in in vitro studies, especially against carbene peptide-resistant Acinetobacter baumannii. Amlodipine hydrochloride can be used in combination with other antibiotics to enhance the inhibitory effect against resistant bacteria. The use of amlodipine hydrochloride helps reduce the dosage requirements of the drug, reduce toxic effects, and delay the emergence of drug resistance .
    Amlodipine hydrochloride
  • HY-N7135
    Tropolone

    		Tyrosinase Fungal Metabolic Disease Inflammation/Immunology Cancer
    Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU 2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
    Tropolone
  • HY-122639
    ZINC05007751
    1 Publications Verification

    		 NEKs Cancer
    ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .
    ZINC05007751
  • HY-143236
    DHFR-IN-1

    		Bacterial Fungal Infection
    DHFR-IN-1 (compound 12) is a potent and selective DHFR (dihydrofolate reductase)inhibitor, with an IC50 of 40.71 nM. DHFR-IN-1 exhibits promising antibacterial activity against gram-positive and gram-negative bacteria. DHFR-IN-1 exhibits moderate antifungal activities. DHFR-IN-1 exhibits a high synergistic effect with Levofloxacin (HY-B0330), where the FIC (fractional inhibitory concentration index) value is 0.249 .
    DHFR-IN-1
  • HY-134978A
    (+)SHIN2
    1 Publications Verification

    		 SHMT Cancer
    (+)SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor, whose target can be traced with 13C-serine. (+)SHIN2 increases survival in NOTCH1-driven mouse primary acute lymphoblastic leukemia (T-ALL) in vivo with a synergistic effect with Methotrexate (HY-14519) . (+)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (+)SHIN2
  • HY-16160
    Cysmethynil

    		Autophagy ICMT Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-133002
    Methyl sterculate

    Sterculic acid methyl ester; Methyl Sterculate

    		 Others Infection
    Sterculic acid methyl ester is an ester form of sterculic acid, which is an inhibitor of Δ9 desaturase. Sterculic acid methyl ester (0.75 mM) inhibits the growth of, and is toxic to, the bacteria R. opacus. It decreases the fatty acid content, increases the ratio of palmitate to other fatty acids, and decreases the levels of stearate and oleate in R. opacus when used at concentrations of 0.25 or 0.5 mM. Sterculic acid methyl ester (50 ppm) has a synergistic effect on increased tumor growth induced by aflatoxin Q1 in rainbow trout.
    Methyl sterculate
  • HY-134914
    Fosmidomycin

    		Antibiotic Parasite Infection
    Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC50s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model .
    Fosmidomycin
  • HY-W131101
    Sorbitan tristearate

    		Liposome Others
    Sorbitan tristearate is a non-ionic surfactant, with a synergistic effect on skin permeability. Sorbitan tristearate can be used as an excipient, such as emulsifier. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Sorbitan tristearate
  • HY-116633
    BCM-599

    		Others Infection
    BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .
    BCM-599
  • HY-118931
    EF-1502

    		GABA Receptor Neurological Disease
    EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .
    EF-1502
  • HY-152293
    EVT801

    		VEGFR ERK Cancer
    EVT801 is an orally active and selective inhibitor of VEGFR-3 (IC50=11 nM), which has antitumor effects. EVT801 inhibits not only VEGF-C-induced human endothelial cell proliferation, but also tumor (lymphatic) angiogenesis in tumor mouse models. EVT801 can reduce tumor hypoxia, immunosuppressive cytokines (CCL4, CCL5) and myeloid derived suppressor cells (MDSC) production. EVT801 has synergistic effect with immune checkpoint therapy (ICT), which improves ICT response rate and has better inhibitory effect on cancer mouse models . EVT801 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    EVT801

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: